⚠ FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION · QUALIFIED RESEARCHERS 21+
// PB-0015 Peptide Growth Hormone

GHRP-2

GH secretagogue · hexapeptide.

GHRP-2 (Growth Hormone Releasing Peptide 2; also called pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist developed by Cyril Bowers' group. It is one of the first growth hormone secretagogues (GHS) developed for research. Supplied as research-grade material with 3rd-party HPLC verification and full Certificate of Analysis per lot.

01

Compound profile.

// CHEMICAL & STRUCTURAL SPEC — GHRP-2
MOLECULAR FORMULA
C45H55N9O6
Peptide · growth hormone class.
MOLECULAR WEIGHT
817.9 Da
Monoisotopic / reported mass.
CHAIN LENGTH
6 aa
Primary structure residues.
ORIGIN
Synthetic · Bowers 1976
Source or discovery context.
STUDIED PATHWAYS
GHSR1a (ghrelin receptor)
Reported in published literature.
REPORTED HALF-LIFE
~15–30 min
Short t½.
HPLC PURITY
99.8%
Minimum release spec · typical >99.9%.
APPEARANCE
White lyo.
White to off-white lyophilized form.
// PRIMARY STRUCTURE
D-Ala–D-2-Nal–Ala–Trp–D-Phe–Lys-NH₂

// D-Ala-D-2-Naphthylalanine-Ala-Trp-D-Phe-Lys amide. A synthetic hexapeptide developed by Cyril Bowers' laboratory. Acts as an agonist of the ghrelin receptor (GHSR1a).
02

What the literature reports.

GHRP-2 (Growth Hormone Releasing Peptide 2; also called pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist developed by Cyril Bowers' group. It is one of the first growth hormone secretagogues (GHS) developed for research.

Reported mechanism

GHRP-2 is an agonist of the growth hormone secretagogue receptor type 1a (GHSR1a), the ghrelin receptor. Published work describes it as stimulating GH release via a mechanism distinct from GHRH — primarily through increased intracellular calcium in pituitary somatotrophs. It is synergistic with GHRH in co-administration studies.

Research context

GHRP-2 is approved in Japan as a diagnostic agent for GH deficiency. In other jurisdictions it remains a research compound. Reported side effects at research doses include transient cortisol and prolactin elevation. WADA prohibited (S2).

The above summarizes published research literature. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.

03

Storage & release.

SHIP TEMP
Ambient
Lyophilized; stable at room temp in transit.
UNOPENED
Refrigerate
Lyophilized, protected from light.
RECONSTITUTED
~28 days
At 2–8°C; never freeze solutions.
RELEASE DOC
COA · per lot
3rd-party analytical · attached at ship.
lab@peptidebros:~$ cat release.ghrp-2.GHRP2-26-Q2-0087.log
// lot release record
compound GHRP-2 (C45H55N9O6)
lot.id GHRP2-26-Q2-0087
class peptide
mw.theoretical 817.9 Da
mw.observed 817.9 Da  [PASS]
purity.hplc 99.91%  [> 99.5% spec]
endotoxin < 0.125 EU/mL  [PASS]
sterility no growth  [PASS]
release.status RELEASED
04

Common questions.

What's the molecular profile?+

GHRP-2 is a 6-residue peptide with molecular formula C45H55N9O6 and molecular weight of approximately 817.9 Da.

The full structural data and release specifications are in the Compound Profile section above. Every lot ships with an independently verified Certificate of Analysis.

How is purity verified?+

Each lot is independently verified by a 3rd-party analytical laboratory (STERIS Labs, Alcami Analytical, or equivalent) before release. Release specification is HPLC purity ≥ 99.5% (typical > 99.8%), mass spectrometry identity match within ±0.5 Da, water content < 5.0% Karl Fischer, and endotoxin < 0.25 EU/mL by LAL (USP <85>).

Look up the full COA for your lot at coa-lookup.html.

How is the compound shipped and stored?+

All compounds ship at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way. Tracked; signature not required.

Store unopened lyophilized product at 2–8°C protected from light. Once reconstituted, most peptides are stable at 2–8°C for approximately 28 days (compound-dependent).

Is this compound FDA-approved?+

GHRP-2 is approved in Japan as a diagnostic agent for GH deficiency. In other jurisdictions it remains a research compound. Reported side effects at research doses include transient cortisol and prolactin elevation. WADA prohibited (S2).

All PeptideBros compounds are sold strictly as chemical reference materials for in-vitro laboratory research. They are not for human consumption.

Every lot,
on paper.

HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.